DOI: 10.4103/hjum.hjum_45_26 ISSN: 0974-1291
Efficacy and Safety of Khamīra Ābresham Sādā in Khafaqān (Palpitation) – A Prospective Clinical Trial
K. Kabiruddin Ahmed, Mustaqueem Khan, Farooqui Shazia Parveen, Athar Parvez Ansari, Shaheen Akhlaq, Akhand Pratap Singh, Noor Zaheer Ahmed, Ghazala Javed Abstract
Background:
Palpitation is a common cardiovascular complaint characterized by abnormal awareness of heartbeat and associated symptoms such as sweating, chest fullness, and dyspnea. In Unani medicine,
Khafaqān
is attributed to humoral imbalance and altered cardiac temperament. This study evaluated the safety and efficacy of
Khamīra Ābresham Sādā
in patients with
Khafaqān
.
Materials and Methods:
A prospective clinical trial was conducted at the Regional Research Institute of Unani Medicine, Chennai. Ninety patients aged 19–60 years with palpitations were enrolled, of whom 84 completed the study.
Khamīra Ābresham Sādā
was administered orally at 5 g twice daily for 14 days. Symptom severity was assessed using a 10-point visual analog scale (VAS) and a 4-point grading scale. Objective parameters included pulse rate and electrocardiogram (ECG). Safety was evaluated through hematological and biochemical investigations.
Results:
Significant reduction (
P
< 0.05) in VAS scores for palpitation and associated symptoms was observed. Mean VAS score decreased from 9.8 ± 0.91 to 1.1 ± 1.13 on Day 14. Mean pulse rate reduced from 85.3 ± 4.45 to 81.0 ± 3.28 beats/min. Complete relief occurred in 51.2%, marked improvement in 45.2%, and partial relief in 3.6% of patients, with no significant adverse events.
Conclusion:
The findings of this preliminary clinical study suggest that
Khamīra Ābresham Sādā
may provide symptomatic benefit in patients with
Khafaqān
(palpitation) and appears to be well tolerated. However, due to the open-label single-arm design and short duration of follow-up, the results should be interpreted as preliminary evidence and require confirmation through larger randomized controlled trials.